Literature DB >> 10321823

Technetium-99m-EC and other potential new agents in renal nuclear medicine.

J K Moran1.   

Abstract

Search for the ideal radiopharmaceutical to measure effective renal plasma flow (ERPF) has been underway since the early 1960s. Although ortho-iodohippuran (OIH) has biological properties suited for measurement of ERPF, the imaging characteristics are less than desirable. With the advent of the molybdenum-99/technetium-99m generators, efforts have focused on the development of a technetium-99m agent to measure ERPF. Over the last 10 to 15 years several promising technetium-99m renal imaging agents have been developed. Early examples of technetium-99m renal agents such as 99mTc-CO2DADS and 99mTc-PAHIDA, although not ideal replacements for OIH, demonstrated that a technetium-99m complex could be actively transported by the renal tubules and provided the impetus for development of new technetium-99m renal agents. The next breakthrough in technetium-99m renal agents was the development of the triamide mercaptide class of chelating agents by Fritzberg et al. To date the most promising compound in this class is mercaptoacetyltriglycine (MAG3). 99mTc-MAG3 is currently the agent of choice, but it is by no means the perfect replacement for OIH. Problems with high plasma protein binding and clearances that are only 50% to 60% of the OIH clearance make measurement of ERPF difficult. The serendipitous discovery that metabolites of the brain agent 99mTc-ethylenedicysteine diethylester (99mTc-L,L-ECD) are rapidly excreted in the urine has led to the evaluation of 99mTc-L,L-ethylenedicysteine (99mTc-L,L-ECD) as a potential renal imaging agent. Studies that have evaluated 99mTc-L,L-EC in animals, normal human volunteers, and patients with various renal disorders reveal that the renal clearance of 99mTc-L,L-EC is higher than 99mTc-MAG3 and more closely approaches that of OIH. Other approaches that are being examined in the development of the ideal renal imaging agent include substitution of various amino acids for glycine residue in MAG3 and technetium-99m labeled organic cations.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10321823     DOI: 10.1016/s0001-2998(99)80002-6

Source DB:  PubMed          Journal:  Semin Nucl Med        ISSN: 0001-2998            Impact factor:   4.446


  5 in total

1.  Relative Ectopic Kidney Function Quantification Using DMSA Tomoscintigraphy Modality.

Authors:  Ines Njeh; Kalil Chtourou; Ahmed BenHamida
Journal:  J Healthc Eng       Date:  2020-05-26       Impact factor: 2.682

2.  Monoanionic 99mTc-tricarbonyl-aminopolycarboxylate complexes with uncharged pendant groups: Radiosynthesis and evaluation as potential renal tubular tracers.

Authors:  Malgorzata Lipowska; Jeffrey Klenc; Nashwa Jarkas; Luigi G Marzilli; Andrew T Taylor
Journal:  Nucl Med Biol       Date:  2016-12-27       Impact factor: 2.408

3.  Comparison of the Relative Renal Function Calculated with 99mTc-Diethylenetriaminepentaacetic Acid and 99mTc-Dimercaptosuccinic Acid in Children.

Authors:  Tanju Çelik; Hülya Yalçin; Emel Ceylan Günay; Aynur Özen; Cahit Özer
Journal:  World J Nucl Med       Date:  2014-09

4.  Can Tc 99m DTPA be Used in Adult Patients in Evaluation of Relative Renal Function Measurement as the Reference Tc 99m DMSA Method?

Authors:  Hülya Yalçın; Aynur Ozen; Emel Ceylan Günay; Inci Aliç Ozaslan; Cahit Ozer
Journal:  Mol Imaging Radionucl Ther       Date:  2011-04-01

5.  Role of Technetium-99m-Ethylenedicysteine in the Calculation of Differential Renal Function: A Comparison Study with Dimercaptosuccinic Acid Renal Scintigraphy.

Authors:  Raheleh Hedayati; Sepideh Hekmat; Fereydoun Rastgou; Nahid Yaghoobi; Hasan Firoozabadi; Ahmad Bitarafan-Rajabi; Hadi Malek; Somaie Arabshameli
Journal:  Indian J Nucl Med       Date:  2021-03-04
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.